Assessing treatment response to interferon-β :Is there a role for MRI?

Neurology

Volumn 82, Issue 3, 2014, Pages 248-254

  Dobson, Ruth ^a,c   Rudick, Richard A ^b   Turner, Ben ^c   Schmierer, Klaus ^a,c   Giovannoni, Gavin ^a,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Mellen Center for Multiple Sclerosis Treatment and Research   (United States)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GADOLINIUM; PLACEBO;

ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROCEDURES; TREATMENT FAILURE; TRENDS;

CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; TREATMENT FAILURE;

EID: 84895740228     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000036     Document Type: Article

References (29)

1. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Longterm efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
2. The IFNBMultiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:655-661.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
4. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
5. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol 2009; 8:889-897.
6. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
7. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
8. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249.
9. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001;357:1576-1582.
10. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-555.
11. Sormani MP, Bruzzi P, Beckmann K, et al. The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. J Neurol 2005; 252:1455-1458.
12. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol 2013;12:669-676.
13. Horakova D, Kalincik T, Dolezal O, et al. Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand 2012;126:390-397.
14. Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: The Roman experience. Neurol Sci 2005;26(suppl 4): S174-S178.
15. Kinkel RP, Simon J, Carulli J, et al. Magnetic resonance imaging activity predicts multiple sclerosis patients' response to treatment with interferon beta-1a (P76). Mult Scler 2008;14:S51.Abstract.
16. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009;16:1202-1209.
17. Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011;77:1684-1690.
18. Tomassini V, Paolillo A, Russo P, et al. Predictors of longterm clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006;253:287-293.
19. Rio J, Rovira A, Tintore M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsingremitting multiple sclerosis patients. Mult Scler 2008;14: 479-484.
20. Durelli L, Barbero P, Bergui M, et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:646-651.
21. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15:848-853.
22. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013;73:95-103.
23. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry Epub 2013 Mar 15.
24. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-256.
25. Goodin DS, Traboulsee A, Knappertz V, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:282-287.
26. Erbayat-Altay E, Fisher E, Lee JC, Hara-Cleaver C, Jones S, Rudick RA. Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a clinic setting. Int J MS Care 2011;13:S113. Abstract.
27. Rudick RA, Rani MR, Xu Y, et al. Excessive biologic response to IFNbeta is associated with poor treatment response in patients with multiple sclerosis. PLoS One 2011;6:e19262.
28. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009;73:372-377.
29. Sbardella E, Tomassini V, Gasperini C, et al. Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: A retrospective study. BMC Neurol 2009;9:54.